• Citer

Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study.

par Ravoet, Christophe;Mineur, Philippe;Robin, Valérie ;Debusscher, L;Bosly, André;André, Marie Josèphe;El Housni, Hakim ;Soree, Anne;Bron, Dominique ;Martiat, Philippe
Référence Annals of hematology, 87, 11, page (881-885)
Publication Publié, 2008-11

Article révisé par les pairs

• Détails
• Contenu

Titre:	Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study.
Auteur:	Ravoet, Christophe; Mineur, Philippe; Robin, Valérie; Debusscher, L; Bosly, André; André, Marie Josèphe; El Housni, Hakim; Soree, Anne; Bron, Dominique; Martiat, Philippe
Informations sur la publication:	Annals of hematology, 87, 11, page (881-885)
Statut de publication:	Publié, 2008-11
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Aged
	Farnesyltranstransferase -- antagonists & inhibitors
	Female
	Gastrointestinal Diseases -- chemically induced
	Genes, ras -- genetics
	Humans
	Leukemia, Myeloid, Acute -- drug therapy
	Male
	Middle Aged
	Myelodysplastic Syndromes -- drug therapy
	Piperidines -- adverse effects
	Pyridines -- adverse effects
Note générale:	Clinical Trial, Phase II
	Journal Article
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0939-5555
	info:doi/10.1007/s00277-008-0536-2
	info:scp/53549126061
	info:pmid/18641985